智翔金泰(688443.SH)：赛立奇单抗注射液纳入2025年国家医保目录

Core Viewpoint - The company Zhixiang Jintai (688443.SH) announced that its self-developed monoclonal antibody injection, Saliqi, has been successfully included in the National Medical Insurance Directory, effective from January 1, 2026 [1] Group 1: Product Information - Saliqi is a recombinant fully human anti-IL-17A monoclonal antibody classified as a Class I therapeutic biological product [1] - The product specifically binds to IL-17A protein in serum, blocking its interaction with IL-17RA, thereby inhibiting the occurrence and development of inflammation [1] - Saliqi is aimed at treating autoimmune diseases characterized by overexpression of IL-17A, such as plaque psoriasis and radiographic axial spondyloarthritis [1]